technical library

Application notes

  1. lattice-an-005 · t cells · benchmark

    Manufacturing of primary T cells in Lattice bioreactors yields high proliferation and clinically desirable phenotype for therapy

    Ekaterini D Zacharis · Daniel Clode · Kim Jee Goh · Aimee Cheesbrough · Joseph D Taylor · Vitor Espirito Santo

    This application note demonstrates the highly efficient ex vivo expansion of primary human T cells using Hoxton Pharma’s proprietary bioreactor platform that meets the unique demands of both autologous and allogeneic immunotherapies. The system achieves primary T cell proliferation rates and critical quality attributes that match or exceed traditional high-cost, single-use static culture systems such as the G-Rex® platform, for different donors tested.

    Key results

    • >1e9 viable T cells

      Expanded from a 50e6 seed stock in 5 days post-inoculation, using a total of only 500 mL of culture media.

    • 30–35% lower media cost

      Reduction in media-associated cost per clinical dose across all three donors tested, versus G-Rex®.

    • >3e6 cells/mL density

      Viable cell density surpassed during the active growth phase, with fold expansion matching or exceeding G-Rex®.

    • Memory-rich T central memory phenotype

      Higher proportion of T central memory and lower T effector memory than G-Rex®, across CD4+ and CD8+ populations.

    Cell type
    Primary human pan-T cells, 3 donors
    System
    Lattice mini, 0.1–0.5 L working volume
    Benchmark
    G-Rex® 10M (Wilson Wolf)
    Readouts
    Fold expansion, metabolites, flow phenotyping, media cost
    Read the note PDF PDF coming soon
  2. lattice-an-004 · cultivated fat · scale-out

    Scaling cultivated fat: industrialising pre-adipocyte expansion and differentiation via Lattice technology

    Aimee Cheesbrough · Kim Goh · Ecem Ozturk · Sam Matthews · Max Crum · Joe Taylor · Vítor Espírito Santo

    This application note demonstrates a highly reproducible and predictable approach to scale manufacturing of adipocytes in suspension using a proprietary, modular scale-out bioreactor system. By combining a gentle, low-shear rocking motion with an invariant 2 L vessel geometry across a 5-batch production campaign, the system establishes a uniform fluidic environment that enables anchorage-dependent preadipocytes to naturally self-assemble into 3D aggregates — eliminating the need for solid microcarriers or complex hollow-fiber architectures, and completely bypassing traditional volumetric scale-up hurdles.

    Key results

    • 5 independent batches

      Each run used an array of 23–36 individual 2 L units, totalling 46–72 L of culture operating simultaneously.

    • 42.14 ± 2.65% lipid content, dry basis

      Gravimetric lipid extraction clustered tightly between 40% and 47% across batches (CV = 6.29%).

    • 35.62 ± 1.88 µm aggregate diameter

      Mean representative aggregate diameter at harvest, with no significant variance across runs (CV = 5.28%).

    • 5.66e5 fold ADIPOQ upregulation

      Relative to pre-inoculation controls, with every replicate achieving >6,700-fold activation.

    Cell type
    Porcine pre-adipocytes (HFP02.2)
    System
    Lattice Production Module, 2 L vessels
    Scale
    46–72 L per batch, 9-day fed-batch process
    Readouts
    Metabolites, aggregation, qPCR, full compositional and microbial panel
    Read the note PDF 9 pages · 1.0 MB
  3. lattice-an-002 · hmscs · microcarriers

    Microcarrier-based expansion of umbilical cord-derived mesenchymal stem cells in Lattice mini bioreactors

    Azin Azarbarzin · Jameel Sardharwalla · Aimee Cheesbrough · Peter Quicke · Kim Jee Goh · Vitor Espirito Santo

    This application note demonstrates a reproducible process for the successful attachment and expansion of hUC-MSCs on microcarriers using the Lattice mini modular bioreactor system. Expanding these cells in Lattice significantly reduces media consumption compared to a traditional 2D process while achieving an equivalent yield and maintaining the MSC phenotype — a cost-effective solution for therapeutic manufacturing.

    Key results

    • ~15× fold expansion

      Average expansion relative to seeding density over a five-day culture, across three independent batches.

    • 62% lower media cost

      Modelled cost to reach 1 billion cells, including carriers — using 70% less media than the 2D route.

    • 93.0% viability at harvest

      Doubling time of 29.9 h in Lattice mini, comparable to 24.6 h in the 2D T-flask control.

    • ~99% CD73 expression

      Above the 95% ISCT minimum, with all negative markers below 1% — no scaffold-induced phenotypic divergence.

    Cell type
    hUC-MSCs on polystyrene microcarriers, 3 batches
    System
    Lattice mini, 210–250 mL working volume
    Benchmark
    2D T-flask and 5-stack culture chambers
    Readouts
    Growth kinetics, live-cell imaging, metabolites, flow cytometry, cost model
    Read the note PDF PDF coming soon
talk to the team

Bring us your process.

Tell us the cell type and the scale you need, and we will show you what a Lattice run looks like for it.

hello@hoxtonpharma.com